Novartis' Ameet Nathwani Joins Sanofi
This article was originally published in Scrip
Executive Summary
Ameet Nathwani has been appointed to Sanofi's executive committee – effective May 1, 2016. Nathwani joins the company from Novartis taking the position of executive vice president, group chief medical officer. From 1994 he held senior leadership roles in research and development in Glaxo, SmithKline Beecham and GlaxoSmithKline PLC. He joined Novartis in 2004 as senior vice president and global development head of the cardiovascular and metabolic franchise and held various senior development and commercial positions over the 11 years he was there. He was appointed global head of medical affairs Novartis Pharma AG in June 2014.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.